{"id":9482,"date":"2026-01-12T16:42:38","date_gmt":"2026-01-12T13:42:38","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9482"},"modified":"2026-01-12T16:42:38","modified_gmt":"2026-01-12T13:42:38","slug":"fda-approves-new-venous-stent-for-deep-venous-disease-in-jan-2026-key-points","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/fda-approves-new-venous-stent-for-deep-venous-disease-in-jan-2026-key-points\/","title":{"rendered":"FDA approves new venous stent for deep venous disease in Jan 2026 \u2013 Key Points"},"content":{"rendered":"<p><span>FDA approves new venous stent for deep venous disease in Jan 2026 \u2013 Key Points<\/span><\/p>\n<p><span>\u2022 A first-of-its-kind FDA approval for a stent specifically designed for deep venous disease, rather than the traditional off-label use of arterial stents.<\/span><br \/>\n<span>\u2022 Designed to treat deep venous disease involving the IVC, iliac, and iliofemoral veins.<\/span><br \/>\n<span>\u2022 Self-expanding<\/span><br \/>\n<span>\u2022 Clinical evidence<\/span><br \/>\n<span>\u2022 FDA decision based on data presented at the VEINS Conference (Nov 2025).<\/span><br \/>\n<span>\u2022 International trial of 89 patients with deep venous disease.<\/span><br \/>\n<span>\u2022 12-month primary patency: 83.4%.<\/span><br \/>\n<span>\u2022 No reported stent embolization\/migration, fractures, vascular injuries, or clinically significant pulmonary embolism.<\/span><\/p>\n<p><a href=\"https:\/\/www.beckershospitalreview.com\/supply-chain\/fda-approves-first-venous-stent-for-ivc-iliofemoral-use.html\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.beckershospitalreview.com\/supply-chain\/fda-approves-first-venous-stent-for-ivc-iliofemoral-use.html&amp;source=gmail&amp;ust=1768311702444000&amp;usg=AOvVaw0hrzRmAqND18fYNIWHdpOP\" rel=\"noopener\">https:\/\/www.<wbr \/>beckershospitalreview.com\/<wbr \/>supply-chain\/fda-approves-<wbr \/>first-venous-stent-for-ivc-<wbr \/>iliofemoral-use.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA approves new venous stent for deep venous disease in Jan 2026 \u2013 Key Points \u2022 A first-of-its-kind FDA approval for a stent specifically designed for deep venous disease, rather than the traditional off-label use of arterial stents. \u2022 Designed to treat deep venous disease involving the IVC, iliac, and iliofemoral veins. \u2022 Self-expanding \u2022 [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9482","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9482"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9482\/revisions"}],"predecessor-version":[{"id":9483,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9482\/revisions\/9483"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}